Percutaneous Tibial Nerve Stimulation

Policy Number: 7.01.106
Origination: 5/2008
Last Review: 11/2018
Next Review: 5/2019

Policy
Blue Cross and Blue Shield of Kansas City (Blue KC) may provide coverage for Percutaneous Tibial Nerve Stimulation when it is determined to be medically necessary because the criteria shown below are met.

Please note that this is a type of electrical stimulation that is considered a benefit exclusion in many health plan contracts.

When Policy Topic is covered
Percutaneous tibial nerve stimulation for an initial 12-week course is considered medically necessary for individuals with non-neurogenic urinary dysfunction including overactive bladder who have both:

- failed behavioral therapy following an appropriate duration of 8 to 12 weeks without meeting treatment goals; and
- failed pharmacologic therapy following 4 to 8 weeks of treatment without meeting treatment goals.

Maintenance therapy using monthly percutaneous tibial nerve stimulation is considered medically necessary for individuals following a 12-week initial course of percutaneous tibial nerve stimulation that resulted in improved urinary dysfunction meeting treatment goals.

When Policy Topic is not covered
Percutaneous tibial nerve stimulation is considered investigational for all indications, including but not limited to the following:

- Neurogenic bladder dysfunction
- Fecal incontinence.

Considerations
Note: There is no separate policy statement for patients with interstitial cystitis, as they would be considered candidates for PTNS therapy based on the presence of urgency and frequency alone.
Patients may be considered to have failed behavioral therapies following an appropriate duration of 8 to 12 weeks without meeting treatment goals (Gormley et al [2015]).

Patients may be considered to have failed pharmacologic therapies following 4 to 8 weeks of treatment without meeting treatment goals (Gormley et al [2015]).

Annual evaluation by a physician may be performed to ensure efficacy is continuing for maintenance percutaneous tibial nerve stimulation treatments.

### Description of Procedure or Service

<table>
<thead>
<tr>
<th>Populations</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
</tr>
</thead>
</table>
| Individuals:  
- With non-neurogenic urinary dysfunction including overactive bladder who have failed behavioral and pharmacologic therapy  
- With overactive bladder syndrome who respond to an initial course of percutaneous tibial nerve stimulation  
- With neurogenic bladder dysfunction  
- With fecal incontinence | Interventions of interest are:  
- Initial course of percutaneous tibial nerve stimulation  
- Maintenance percutaneous tibial nerve stimulation  
- Percutaneous tibial nerve stimulation | Comparators of interest are:  
- Sacral nerve stimulation  
- Botulinum toxin  
- Conservative therapies  
- Medication  
- Sacral nerve stimulation  
- Botulinum toxin  
- Conservative therapies  
- Medication  
- Sacral nerve stimulation  
- Botulinum toxin  
- Conservative therapies  
- Medication  
- Sacral nerve stimulation  
- Botulinum toxin | Relevant outcomes include:  
- Symptoms  
- Change in disease status  
- Functional outcomes  
- Quality of life  
- Treatment-related morbidity  
- Symptoms  
- Change in disease status  
- Functional outcomes  
- Quality of life  
- Treatment-related morbidity  
- Symptoms  
- Change in disease status  
- Functional outcomes  
- Quality of life  
- Treatment-related morbidity  
- Symptoms  
- Change in disease status  
- Functional outcomes  
- Quality of life  
- Treatment-related morbidity |

Percutaneous tibial nerve stimulation (PTNS; also known as posterior tibial nerve stimulation) is a technique of electrical neuromodulation used primarily for treating voiding dysfunction.
For individuals who have non-neurogenic urinary dysfunction including overactive bladder who have failed behavioral and pharmacologic therapy who receive an initial course of PTNS, the evidence includes randomized sham-controlled trials, randomized controlled trials (RCTs) with an active comparator, and systematic reviews. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. The Sham Effectiveness in Treatment of Overactive Bladder Symptoms and the Overactive Bladder Innovative Therapy trials are 2 key industry-sponsored RCTs. Systematic reviews that include these trials and other published trials have found short-term improvements with PTNS. The largest, highest quality study was the double-blinded, sham-controlled Sham Effectiveness in Treatment of Overactive Bladder Symptoms trial. It reported a statistically significant benefit of PTNS vs sham at 12 weeks. In an additional small sham-controlled trial, a 50% reduction in urge incontinent episodes was attained in 71% of PTNS group compared with 0% in the sham group. The nonblinded Overactive Bladder Innovative Therapy trial found that PTNS was noninferior to medication treatment at 12 weeks. Adverse events were limited to local irritation effects. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Clinical input obtained in 2018 supports that the following indication provides a clinically meaningful improvement in net health outcome and is consistent with generally accepted medical practice.

- Use of monthly maintenance PTNS for individuals with non-neurogenic urinary dysfunction including overactive bladder who have failed behavioral and pharmacologic therapy who respond to an initial course of percutaneous tibial nerve stimulation.

Thus, the above indication may be considered medically necessary considering the evidence and clinical input support.

For individuals who have overactive bladder syndrome that has failed behavioral and pharmacologic therapy who respond to an initial course of PTNS who receive maintenance PTNS, the evidence includes observational studies and systematic reviews. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. The Sham Effectiveness in Treatment of Overactive Bladder Symptoms and the Overactive Bladder Innovative Therapy trials each included extension studies that followed individuals who responded to the initial course of PTNS and continued to receive periodic maintenance therapy. There is variability in the interval between and frequency of maintenance treatments, and an optimal maintenance regimen remains unclear. There are up to 36 months of observational data available, reporting that there is a durable effect for some of these patients. While comparative data are not available after the initial 12-week treatment period, the observational data support a clinically meaningful benefit for use in individuals who have already failed behavioral and pharmacologic therapy and who respond to the initial course of PTNS. PTNS may allow such individuals to avoid more invasive interventions.
Adverse events appear to be limited to local irritation for both short and long-term PTNS use. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have neurogenic bladder dysfunction who receive PTNS, the evidence includes several RCTs and a systematic review of RCTs and observational data. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Only a few RCTs evaluating tibial nerve stimulation for treating neurogenic bladder have been published to date, and all but one performed transcutaneous stimulation rather than PTNS. Studies varied widely in factors, such as the study populations and comparison interventions. Study findings have not reported that tibial nerve stimulation significantly improved incontinence symptoms and other outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have fecal incontinence who receive PTNS, the evidence includes several RCTs and systematic reviews. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. The available RCTs have not found a clear benefit of PTNS. Neither of the sham-controlled trials found that active stimulation was superior to sham for achieving the primary outcome, at least a 50% reduction in mean weekly fecal incontinence episodes. The larger sham-controlled randomized trial did find a significantly greater decrease in the absolute number of weekly incontinence episodes in the active treatment group, but the overall trial findings did not suggest the superiority of PTNS over sham treatment. Systematic reviews have not conducted pooled analyses. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Background**

**Voiding Dysfunction**

Common causes of non-neurogenic voiding dysfunction are pelvic floor neuromuscular changes (eg, from pregnancy, childbirth, surgery), inflammation, medication (eg, diuretics, anticholinergics), obesity, and psychogenic factors. Overactive bladder is a non-neurogenic voiding dysfunction characterized by urinary frequency, urgency, urge incontinence, and nonobstructive retention. Neurogenic bladder dysfunction is caused by neurologic damage in patients with multiple sclerosis, spinal cord injury, detrusor hyperreflexia, or diabetes with peripheral nerve involvement. The symptoms include overflow incontinence, frequency, urgency, urge incontinence, and retention.

**Treatment**

Approaches to the treatment of incontinence differentiate between urge incontinence and stress incontinence. Conservative behavioral management such as lifestyle modification (eg, dietary changes, weight reduction, fluid management, smoking cessation) along with pelvic floor exercises and bladder training are part of the initial treatment of overactive bladder symptoms and both types of
incontinence. Pharmacotherapy is another option, and different medications target different symptoms. Some individuals experience mixed incontinence.

If behavioral therapies and pharmacotherapy are unsuccessful, percutaneous tibial nerve stimulation (PTNS), sacral nerve stimulation, or botulinum toxin may be recommended.

**Percutaneous Tibial Nerve Stimulation**
The current indication cleared by the U.S. Food and Drug Administration (FDA) for PTNS is overactive bladder and associated symptoms of urinary frequency, urinary urgency, and urge incontinence.

Altering the function of the posterior tibial nerve with PTNS is believed to improve voiding function and control. The mechanism of action is believed to be retrograde stimulation of the lumbosacral nerves (L4-S3) via the posterior tibial nerve located near the ankle. The lumbosacral nerves control the bladder detrusor and perineal floor.

Administration of PTNS consists of inserting a needle above the medial malleolus into the posterior tibial nerve followed by the application of low-voltage (10 mA, 1-10 Hz frequency) electrical stimulation that produces sensory and motor responses as evidenced by a tickling sensation and plantarflexion or fanning of all toes. Noninvasive PTNS has also been delivered with transcutaneous or surface electrodes. The recommended course of treatment is an initial series of 12 weekly office-based treatments followed by an individualized maintenance treatment schedule.

PTNS is less invasive than traditional sacral nerve neuromodulation (see evidence review 7.01.69), which has been successfully used to treat urinary dysfunction but requires implantation of a permanent device. In sacral root neuromodulation, an implantable pulse generator that delivers controlled electrical impulses is attached to wire leads that connect to the sacral nerves, most commonly the S3 nerve root that modulates the neural pathways controlling bladder function.

PTNS has also been proposed as a treatment for non-neurogenic and neurogenic bladder syndromes and fecal incontinence.

**Regulatory Status**
In 2005, the Urgent® PC Neuromodulation System was the initial PTNS device cleared for marketing by FDA through the 510(k) process to treat patients suffering from urinary urgency, urinary frequency, and urge incontinence. Additional percutaneous tibial nerve stimulators have been cleared for marketing through the 510(k) process. They are listed in Table 1.

The Urgent® PC Neuromodulation System and NURO™ Neuromodulation System are not FDA-cleared for other indications, such as the treatment of fecal incontinence.
Wireless technology is evolving for the treatment of overactive bladder; it is approved in Europe. BlueWind (BlueWind Medical) is a wireless, battery-less, miniature implantable neurostimulator activated by an external device worn at the ankle.

Table 1. FDA-Cleared Percutaneous Tibial Nerve Stimulators (FDA Product Code: NAM)

<table>
<thead>
<tr>
<th>Device Name</th>
<th>Manufacturer</th>
<th>Cleared</th>
<th>510(k)</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urgent® PC Neuromodulation System</td>
<td>Uroplasty, now Cogentix Medical</td>
<td>Oct 2005</td>
<td>K052025</td>
<td>Treatment of urinary urgency, urinary frequency, and urge incontinence</td>
</tr>
<tr>
<td>Urgent® PC Neuromodulation System</td>
<td>Uroplasty, now Cogentix Medical</td>
<td>Jul 2006</td>
<td>K061333</td>
<td>FDA determined the 70% isopropyl alcohol prep pad contained in the kit is subject to regulation as a drug</td>
</tr>
<tr>
<td>Urgent® PC Neuromodulation System</td>
<td>Uroplasty, now Cogentix Medical</td>
<td>Aug 2007</td>
<td>K071822</td>
<td>Labeling update, intended use is unchanged</td>
</tr>
<tr>
<td>Urgent® PC Neuromodulation System</td>
<td>Uroplasty, now Cogentix Medical</td>
<td>Oct 2010</td>
<td>K101847</td>
<td>Intended use statement adds the diagnosis of overactive bladder</td>
</tr>
<tr>
<td>NURO™ Neuromodulation System</td>
<td>Advanced Uro-Solutions, now Medtronic</td>
<td>Nov 2013</td>
<td>K132561</td>
<td>Treatment of patients with overactive bladder and associated symptoms of urinary urgency, urinary frequency, and urge incontinence</td>
</tr>
</tbody>
</table>

FDA: Food and Drug Administration.

Rationale

This evidence review was created in July 2006 and has been updated regularly with searches of the MEDLINE database. The most recent literature updated was performed through June 4, 2018.

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function—including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCTs) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long
enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Non-Neurogenic Urinary Dysfunction Including Overactive Bladder

Clinical Context and Therapy Purpose

The purpose of percutaneous tibial nerve stimulation (PTNS) in patients who have non-neurogenic urinary dysfunction including overactive bladder (OAB) and have failed behavioral and pharmacologic therapy or OAB who have responded to an initial course of PTNS, is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does the use of PTNS improve the net health outcome in patients with non-neurogenic urinary dysfunction including OAB and have failed behavioral and pharmacologic therapy or those with OAB who have responded to an initial course of PTNS?

The following PICOTS were used to select literature to inform this review.

Patients

The relevant populations of interest are:

- Patients who have non-neurogenic urinary dysfunction including OAB who have failed behavioral and pharmacologic therapy and
- Patients with OAB responsive to an initial course of PTNS.

Interventions

The therapy being considered is PTNS as an initial or maintenance therapy. During PTNS, a needle is inserted above the medial malleolus into the posterior tibial nerve followed by the application of low-voltage (10 mA, 1-10 Hz frequency) electrical stimulation. Noninvasive PTNS may be delivered with transcutaneous or surface electrodes. The recommended course of treatment is an initial series of 12 weekly office-based treatments followed by an individualized maintenance treatment schedule.

Comparators

The following therapies are currently being used to make decisions about non-neurogenic urinary dysfunction: botulinum toxin and sacral nerve stimulation (SNS).

Botulinum toxin is injected into the detrusor muscle. However, the toxin increases the risk of urinary retention and is not recommended for patients with a history of urinary retention or recurrent urinary tract infections.

SNS may be conducted in an outpatient clinical setting using temporary wire leads. Due to the incidence of lead migration, a 2-step process in a surgical setting is recommended. In the initial test phase, wire leads are inserted under the skin and
if 50% improvement is reported, the patient may elect permanent implantation with a pacemaker-like stimulator. If the test phase is unsuccessful, the leads are then removed.

**Outcomes**
The general outcomes of interest are reductions in symptoms (eg, self-reported assessment of symptoms, decrease in number of voids per day) and improved quality of life.

**Timing**
Outcomes are measured following the 12-week treatment regimen.

**Setting**
PTNS is administered in an outpatient clinical setting.

**Sham-Controlled Randomized Trials**
The Sham Effectiveness in Treatment of Overactive Bladder Symptoms (SUmiT) trial, reported by Peters et al (2010), was a sham-controlled randomized trial. Before conducting the trial, investigators performed a pilot study in healthy volunteers to determine the adequacy of a sham PTNS intervention. The sham procedure was correctly identified by 10 (33%) of 30 volunteers. This percentage is below the 50% that could be expected by chance, so investigators concluded that the procedure was a feasible sham. Eligibility criteria included: a score of 4 or more on the Overactive Bladder Questionnaire Short Form for urgency, self-reported bladder symptoms lasting at least 3 months, and having failed conservative care for these symptoms or a diagnosis of OAB. OAB and quality of life questionnaires, as well as 3-day voiding diaries, were completed at baseline and 13 weeks.

Both the randomized sham and active intervention groups received 12 weekly 30-minute intervention sessions. In the sham group, a blunt (placebo) instrument was used to simulate the location and sensation of needle electrode insertion in active treatment. One inactive PTNS surface electrode and 2 active transcutaneous electrical nerve stimulation surface electrodes were used. The transcutaneous electrical nerve stimulation unit (Urgent PC system) delivered low-level stimulation to mimic the PTNS intervention. The 12-week treatment was completed by 103 (94%) of 110 in the PTNS group and 105 (95%) of 110 in the sham group.

The primary trial end point was an efficacy assessment measured by a 7-level global response assessment (GRA) tool, in which patients reported change in symptoms as markedly worse, moderately worse, mildly worse, the same, slightly improved, moderately improved, or markedly improved. A responder was defined as one who reported symptoms as moderately or markedly improved at week 13. The rate of responders was 54.5% (60/110) of PTNS subjects compared with 20.9% (23 of 110) of sham subjects. There was a statistically significant benefit reported with PTNS compared with sham treatment in voiding diary variables as well.
Six PTNS subjects reported 9 mild or moderate treatment-related adverse events consisting of ankle bruising, discomfort at the site of needle insertion, bleeding at the site, and tingling in the leg. No local treatment-related adverse events were reported in the sham group, and no systemic adverse events occurred in either group.

The Sustained Therapeutic Effects of Percutaneous Tibial Nerve Stimulation (STEP) trial, an extension of the SUmiT study, included only responders from the PTNS group. The purpose was to determine the threshold for maintenance therapy. Of the 60 PTNS group 13-week responders, 50 entered the extension study. Patients underwent a 14-week transitional protocol consisting of 2 treatments with a 14-day interval, 2 treatments with a 21-day interval, and then 1 treatment after another 28 days. Following this 14-week period, a personal treatment plan was developed for each patient. PTNS was delivered when patients reported that their symptoms increased. Between 6 and 36 months, patients received a median of 1.1 monthly PTNS treatments after the 14-week tapering period. Data were available on 34 patients at 24 months and on 29 patients at 36 months. In a per-protocol analysis, compared with baseline, 28 (97%) of 29 patients who completed the 36-month follow-up met the primary efficacy endpoint of moderate or marked improvement in overall bladder symptoms on the GRA. Also, compared with baseline, all voiding diary measures were significantly improved in this group of patients at every 6-month follow-up.

Adverse events noted in the STEP study included 1 report of restricted vaginal opening with unknown relation to treatment and 2 mild bleeding events at the needle site in the same participant. Nine patients reported 11 mild adverse events with an unknown relation to treatment including vaginal bleeding, mild depression, shoulder pain, diarrhea, leg pain, stomach ache, pelvic pain, urinary tract infection, a pulling sensation in both feet, bladder pressure, and pinched nerve pain.

A limitation of the SUmiT trial was that the primary outcome (the GRA) is a single-item subjective measure. An additional limitation was that only short-term comparative data were available. And unlike medication that can be taken in the same manner on an ongoing basis, PTNS involves an initial 12-week course of treatment followed by maintenance therapy, which varies from the initial treatment course. To date, maintenance therapy has not been well defined.

Tables 2 and 3 summarize the SUmiT RCT and STEP extension study.

### Table 2. Summary of SUmiT RCT and STEP Extension Characteristics

<table>
<thead>
<tr>
<th>Study; Trial</th>
<th>Countries</th>
<th>Site(s)</th>
<th>Dates</th>
<th>Randomized or Enrolled/ Completed Trial</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peters et al</td>
<td>U.S.</td>
<td>23</td>
<td>2008-2009</td>
<td>PTNS 110/103; Sham 110/105</td>
<td>GRA at 13 wk</td>
</tr>
<tr>
<td>(2010) SUmiT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peters et al</td>
<td>U.S.</td>
<td>23</td>
<td>2009-2012</td>
<td>PTNS 50/29; Sham None</td>
<td>GRA at 36 mo</td>
</tr>
<tr>
<td>(2013) STEP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
GRA: global response assessment; PTNS: percutaneous tibial nerve stimulation; RCT: randomized controlled trial; STEP: Sustained Therapeutic Effects of Percutaneous Tibial Nerve Stimulation; SUmiT: Sham Effectiveness in Treatment of Overactive Bladder Symptoms.

Table 3. Summary of SUmiT RCT and STEP Extension Results

<table>
<thead>
<tr>
<th>Study</th>
<th>Primary Outcome: Moderately or Markedly Improved GRA</th>
<th>PTNS, n/N (%)</th>
<th>Sham, n/N (%)</th>
<th>Confidence Intervals</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUmiT (2010)²</td>
<td></td>
<td>60/110 (54.5)</td>
<td>23/110 (20.9)</td>
<td>NR</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>GRA (13 wk)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STEP (2013)³</td>
<td></td>
<td>28/29 (97)</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

GRA: Global response assessment; NR: not reported; PTNS: percutaneous tibial nerve stimulation; RCT: randomized controlled trial; STEP: Sustained Therapeutic Effects of Percutaneous Tibial Nerve Stimulation; SUmiT: Sham Effectiveness in Treatment of Overactive Bladder Symptoms.

An RCT by Finazzi-Agro et al (2010) evaluated 35 women who had urge incontinence and detrusor overactivity on urodynamic testing. Patients were randomized to 30-minute PTNS sessions, 3 times per week for 4 weeks (n=18) or sham treatment (n=17). One patient dropped out of the PTNS group, and 2 dropped out of the sham group; analysis was not intention-to-treat. The primary outcome, percent responders at 4 weeks (defined as at least 50% reduction in incontinent episodes), was attained by 12 (71%) of 17 in the PTNS group and 0 (0%) of 15 in the sham group.

Other RCTs
An RCT comparing PTNS with medication for the treatment of OAB was published by Vecchioli-Scaldazza et al (2018). This 3-arm trial compared solifenacin (n=27), PTNS (n=34), and a combination of solifenacin plus PTNS (n=33) and followed patients through 10 months posttreatment. Patients in all 3 arms experienced significant reductions from baseline in daytime frequency, night-time frequency, and urgency. PTNS was more effective than solifenacin alone, and the combination of PTNS plus solifenacin was more effective than PTNS alone. The combination therapy also showed the longest effect.

A group of RCTs has compared PTNS with an alternative treatment, medication, conservative therapy, or electrical stimulation. The trials reported inconsistent findings on short-term efficacy, and only one reported on the efficacy of PTNS beyond 12 weeks.

Three studies used medication as the comparison intervention. Preyer et al (2015) published a nonblinded study comparing 12 weeks of PTNS with tolterodine in 36 women who had OAB. There were no significant differences between groups on the reduction of incontinence episodes in 24 hours (p=0.89) or quality of life (p=0.07).

Another RCT comparing PTNS with medication—in this case, oral solifenacin—was a crossover trial published by Vecchioli-Scaldazza et al (2013). Forty women with OAB received PTNS (twice weekly for 6 weeks) or medication, given in random...
order, with a 6-week washout period between treatments. Group A received medication first, and group B received PTNS first. The primary efficacy outcome was a reduction in the number of voids in a 24-hour period. Thirty (75%) of the 40 patients completed the trial. The number of daily voids (the primary outcome) significantly decreased after each treatment compared with before treatment. Also, secondary outcomes, including nocturia urge incontinence and voided volume, significantly improved after each treatment compared with pretreatment values. The authors did not directly compare the efficacy of medication with PTNS.

An RCT compared PTNS with conservative therapy. Schreiner et al (2010) assessed 51 women older than 60 years of age who complained of urge urinary incontinence. Women were randomized to 12 weeks of conservative treatment (Kegel exercises, bladder training) alone (n=26) or conservative treatment plus 12 weekly sessions of PTNS (n=25). Blinding was not discussed. The response rate at 12 weeks, defined as a reduction of at least 50% in the number of incontinence episodes reported by the patient in a bladder diary, was 76% in the PTNS group and 27% in the conservative treatment-only group (p=0.001).

Gungor Ugurlucan et al (2013) in Turkey compared transvaginal electrical stimulation (n=38) with PTNS (n=21) in women who had OAB. The electrical stimulation protocol consisted of 20-minute treatments, 3 times a week for 6 to 8 weeks. PTNS was performed with an Urgent PC device used for 12 weekly, 30-minute sessions. Fifty-two (88%) of 59 patients completed the trial. The authors assessed numerous outcome variables and did not specify primary outcomes or adjust p values for multiple comparisons. Four bladder diary variables were reported. From baseline to the end of the treatment period, the groups did not differ significantly in mean change in urgency episodes, nocturia, or incontinence episodes. The mean number of urgency episodes was 2.9 at baseline and 1.6 after treatment in the electrical stimulation group, and 2.0 at baseline and 1.3 after treatment in the PTNS group (p=0.54). The mean daytime frequency was 7.8 at baseline and 5.8 after treatment in the electrical stimulation group, and 7.6 at baseline and 7.4 in the PTNS group (p=0.03). The authors reported that a significantly higher proportion of patients in the electrical stimulation group described themselves as cured, but they did not provide proportions or p values.

The Overactive Bladder Innovative Therapy (OrBIT) trial is the largest randomized trial that was not sham-controlled. This trial was a nonblinded comparison of PTNS and extended-release tolterodine (Detrol LA) in women with OAB. Eligibility included symptoms of OAB, with at least 8 voids per 24 hours; the mean daily voids for those entering the study were 12.3. A total of 100 participants were randomized, with 87 completing the trial. In the PTNS arm, subjects received 12 weekly 30-minute treatments. PTNS parameters were maximized based on patient motor and sensory responses. Subjects on tolterodine received a 90-day prescription for 4 mg daily with a subsequent decrease to 2 mg daily if intolerability was experienced. Voiding diary data were available for 84 participants; 41 (82%) of 50 in the PTNS group and 43 (86%) of 50 in the tolterodine group.
The primary outcome was the noninferiority of PTNS in the mean reduction in the number of voids per 24 hours after 12 weeks of treatment. Noninferiority was defined as no more than a 20% difference in the mean void reduction. As expected the mean reduction in voids of 1.8 for tolterodine and 3.6 for PTNS was based on previously published efficacy data. Study findings showed the noninferiority of PTNS based on results for 84 participants.

The trial also reported on secondary outcomes. There were no statistically significant differences between the PTNS and tolterodine groups for other symptoms recorded in the voiding diary. Improvement in all OAB symptom episodes was statistically significant within each group from baseline to 12 weeks, but not between groups.

The OrBIT trial lacked blinding of patients and providers and lacked comparative data beyond the end of the initial 12-week treatment period. There was no sham or placebo group to mitigate the potential bias due to subjective outcomes. Also, the trialists did not clearly define criteria for “improvement” or “cure” (a key secondary outcome) and did not report the extent of compliance with medical therapy. Finally, different data collection methods were used in the 2 groups (eg, for adverse event outcomes and possibly for other self-reported outcomes).

MacDiarmid et al (2010) reported on 1-year follow-up data for patients from the OrBIT trial who had been assigned to the PTNS group and had reported symptom improvement at 12 weeks. Of the 35 responders, 33 were included. They received a mean of 12.1 additional treatments between the 12-week and 12-month visits, and there was a median of 17 days between treatments. Data were available for 32 (97%) of the 33 participants at 6 months and 25 (76%) of the 33 participants at 12 months.

As noted, this analysis lacked data from the tolterodine group to assess long-term outcomes. Additionally, not all patients in the PTNS group were included in the follow-up analysis; rather, only PTNS responders were eligible. A potential bias is that the initial subjective outcome measure might have been subject to the placebo effect. Moreover, patients in the PTNS group who responded to initial treatment might have been particularly susceptible to a placebo response and/or might represent those with the best treatment response. Thus, these individuals might also have been susceptible to a placebo response during maintenance treatments, especially treatments offered on an as-needed basis.

Tables 4 and 5 summarize the OrBIT and OrBIT 1-year follow-up studies.

### Table 4. Summary of OrBIT RCT Characteristics

<table>
<thead>
<tr>
<th>Study</th>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Randomized/Completed</th>
<th>PTNS</th>
<th>Tolterodine</th>
<th>Outcomea Reduction in Voids</th>
</tr>
</thead>
</table>
Table 5. Summary of OrBIT RCT Results

<table>
<thead>
<tr>
<th>Study</th>
<th>Primary Outcome: Mean Reduction in Voids per Day (SD)</th>
<th>Tolterodine (n=43)</th>
</tr>
</thead>
<tbody>
<tr>
<td>OrBIT (2009)(^1)</td>
<td>PTNS (n=41)</td>
<td></td>
</tr>
<tr>
<td>Voids per day</td>
<td>Baseline 12 Weeks</td>
<td>Baseline 12 Weeks</td>
</tr>
<tr>
<td></td>
<td>12.1 (3.1) -2.4 (4.0)</td>
<td>12.5 (3.7) -2.5 (3.9)</td>
</tr>
<tr>
<td></td>
<td>p&lt;0.001</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Confidence interval</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>OrBIT 1-y follow-up (2010)(^2)</td>
<td>PTNS (n=25)</td>
<td></td>
</tr>
<tr>
<td>Voids per day</td>
<td>Baseline 12 Months</td>
<td>Not applicable</td>
</tr>
<tr>
<td></td>
<td>12.4 (3.5) -2.8 (3.7)</td>
<td>Not applicable</td>
</tr>
<tr>
<td></td>
<td>p&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Confidence interval</td>
<td>NR</td>
<td></td>
</tr>
</tbody>
</table>

NR: not reported; OrBIT: Overactive Bladder Innovative Therapy, PTNS: percutaneous tibial nerve stimulation; RCT: randomized controlled trial.

**Systematic Reviews**

Tutulo et al (2018) searched the literature through December 2017 and identified 21 studies using either sacral neuromodulation (also called SNS) or PTNS to treat lower urinary tract dysfunction and chronic pelvic pain not responding to standard therapies.\(^13\) Reviewers concluded that both SNS and PTNS were effective therapies. PTNS demonstrated higher success rates (≥50% reduction in leakage episodes) and fewer side effects compared with SNS; however, longer follow-up studies with PTNS are needed. Another systematic review by Tutulo et al (2018) conducted a literature search through December 2017 of RCTs evaluating SNS and PTNS for the treatment of OAB unresponsive to standard medical therapy.\(^14\) Five RCTs were identified. Reviewers concluded that both SNS and PTNS, with success rates ranging from 61% to 90% and 54% to 79%, respectively, could be considered effective.

A Cochrane review by Stewart et al (2016) evaluated electrical stimulation with nonimplanted electrodes for OAB in adults.\(^15\) The literature search was current up to December 2015. The objective of the review was to determine whether electrical stimulation (including vaginal and rectal electrical stimulation, and PTNS) was better than no treatment or better than any other treatment available for OAB. Studies reviewed were RCTs or quasi-RCTs of electrical stimulation that included adults with OAB with or without urgency and urge urinary incontinence. Trials whose participants had stress urinary incontinence were excluded. Sixty-three eligible trials were identified (total N=4424 randomized participants). Reviewers included several trials discussed above: the OrBIT (Peters et al [2009]) and OrBIT follow-up (MacDiarmid et al [2010]) trials, SUmiT (Peters et al [2010]) trial, STEP (Peters et al [2013]) trial, and the Finazzi-Agro et al (2010), Schreiner et al (2010), Vecchioli-Scaldazza et al (2013), and Preyer et al (2015) trials.
Data were obtained from the end of treatment and the longest available follow-up period. The primary outcomes identified were the perception of cure, the perception of improvement, and condition-related quality of life measures as defined by the original authors or by any validated measurement scales such as the International Consultation on Incontinence Questionnaire. Secondary outcomes pertinent to the evidence review were a quantification of symptoms, procedure outcome measures, and adverse events.

The key findings from the Cochrane review (2016) of evidence are summarized in Table 6. PTNS results were combined for vaginal and rectal electrical stimulation.

Table 6. Summary of Cochrane Systematic Review Outcomes

<table>
<thead>
<tr>
<th>Comparators to Electrical Stimulation</th>
<th>Electrical Stimulation Effect</th>
<th>QOE</th>
</tr>
</thead>
<tbody>
<tr>
<td>No active treatment, placebo, or sham</td>
<td>Reduction in OAB symptoms</td>
<td>More effective</td>
</tr>
<tr>
<td></td>
<td>Reduction in urge urinary incontinence</td>
<td>More effective</td>
</tr>
<tr>
<td></td>
<td>Improvement in OAB-related quality of life</td>
<td>More effective</td>
</tr>
<tr>
<td>Pelvic floor muscle training</td>
<td>Reduction in OAB symptoms</td>
<td>More effective</td>
</tr>
<tr>
<td></td>
<td>Reduction in urge urinary incontinence</td>
<td>Effect uncertain</td>
</tr>
<tr>
<td></td>
<td>Improvement in OAB-related quality of life</td>
<td>Effect uncertain</td>
</tr>
<tr>
<td>Drug therapy</td>
<td>Reduction in OAB symptoms</td>
<td>More effective</td>
</tr>
<tr>
<td></td>
<td>Reduction in urge urinary incontinence</td>
<td>Effect uncertain</td>
</tr>
<tr>
<td></td>
<td>Improvement in OAB-related quality of life</td>
<td>Effect uncertain</td>
</tr>
<tr>
<td>Oxybutynin or tolterodine</td>
<td>Adverse events</td>
<td>Lower risk</td>
</tr>
<tr>
<td></td>
<td>Placebo/sham</td>
<td>Lower risk</td>
</tr>
</tbody>
</table>


Forty-four trials did not report the primary outcomes of perception of cure or improvement in OAB. The majority of trials were deemed to be at low or unclear risk of selection and attrition bias and unclear risk of performance and detection bias. Lack of clarity regarding the risk of bias was largely due to poor reporting. Many studies did not report whether electrical stimulation was safer than other treatments or if one type of electrical stimulation was safer than others.

This review was informed by a TEC Assessment (2013) evaluating PTNS as a treatment for voiding dysfunction.16 It concluded that PTNS as a treatment for voiding dysfunction met TEC criteria and showed that PTNS improves the net health outcome. Specifically, PTNS ameliorated symptoms of chronic OAB or urinary voiding dysfunction, simultaneously improving quality of life parameters among patients who have failed behavioral and pharmacologic therapies.

In this assessment of 6 RCTs, TEC reviewers drew the following conclusion about the evidence:
“Evidence from randomized placebo-controlled trials supports the clinical
efficacy of PTNS applied in the standard 12-week regimen. No concurrently
controlled evidence exists from a trial over longer periods of time in
maintenance therapy. Although the lack of controlled evidence on
maintenance PTNS raises concern whether short-term efficacy is maintained
over the long term, the available 12- to 36-month evidence appears
consistent with maintained efficacy in relieving symptoms of OAB and
urinary voiding dysfunction. Adverse event rates, assuming accurate
ascertainment, appear limited.”

In 2012 and 2013, several other systematic reviews of the literature on PTNS for
treating OAB were published. Only one conducted pooled analyses of study
results. This review, by Burton et al (2012), conducted a pooled analysis of data
from 4 trials (two of which were abstracts) comparing PTNS with sham treatment.
Reviewers found a significantly higher risk of successful treatment with PTNS
(relative risk, 7.02; 95% confidence interval [CI], 1.69 to 29.17) compared with a
control intervention. The CI was wide, indicating a lack of precision in the pooled
estimate. The patient samples in these studies were homogenous by sex, severity
and duration of symptoms, and previous treatment history. The definition of
successful treatment also varied among studies. The SUmiT trial (discussed above)
contributed 220 (76%) of 289 patients in the pooled analysis.

Also, Shamliyan et al (2012) conducted a comparative effectiveness review for the
Agency for Healthcare Research and Quality on the broader topic of nonsurgical
treatments for urinary incontinence in adult women. Reviewers identified 4 RCTs
comparing PTNS with no active treatment in patients with OAB. Two of the 4 RCTs
reported 12-week results of the sham-controlled SUmiT trial; one of them included
a subgroup of SUmiT participants and was only published as an abstract. The
Shamliyan report included a pooled analysis of data from 3 studies that found
statistically significant improvement in urinary incontinence in the PTNS group
compared with the control group (relative risk, 1.9; 95% CI, 1.1 to 3.2). This
pooled analysis included 405 patients: 220 in the SUmiT trial, 150 in the SUmiT
trial subgroup analysis, and 35 in a trial by Finazzi-Agro et al (2010). A limit of
the Shamliyan et al (2012) analysis was that the 150 patients in the SUmiT
subgroup analysis were included twice. The Shamliyan review did not discuss
evidence on the efficacy of PTNS beyond 12 weeks.

Section Summary: Non-Neurogenic Urinary Dysfunction Including OAB

Initial Course of PTNS
For individuals who have non-neurogenic urinary dysfunction including OAB who
have failed behavioral and pharmacologic therapy and received an initial course of
PTNS, a number of RCTs of PTNS have been published, including 2 key industry-
sponsored RCTs, the OrBIT and SUmiT trials. Systematic reviews of the evidence
have found short-term improvements with PTNS. The largest, highest quality
study was the blinded sham-controlled SUmiT trial. This trial reported a
statistically significant benefit of PTNS vs sham at 12 weeks. In another small
sham-controlled trial, a 50% reduction in urge incontinent episodes was attained in 71% of the PTNS group compared with 0% in the sham group. The nonblinded OrBIT trial found that PTNS was noninferior to medication treatment at 12 weeks.

**Maintenance Course of PTNS**

For individuals who have OAB syndrome who have failed behavioral and pharmacologic therapy, respond to an initial course of PTNS, and then receive maintenance PTNS therapy, there are up to 36 months of observational data that suggest there is a durable effect for some of these patients. The SUmiT and OrBIT trials each included extension studies, which followed individuals who responded to the initial course of PTNS and continued to receive periodic maintenance therapy. There is variability in the interval between and frequency of maintenance treatments, and an optimal maintenance regimen remains unclear. While comparative data are not available after the initial 12-week treatment period, the observational data support a clinically meaningful benefit for use in individuals who have already failed behavioral and pharmacologic therapy and respond to the initial course of PTNS. PTNS may allow such individuals to avoid more invasive interventions. Adverse events appear to be limited to local irritation for both short- and long-term PTNS use.

**Neurogenic Bladder Dysfunction**

**Clinical Context and Therapy Purpose**

The purpose of PTNS in patients who have neurogenic bladder dysfunction is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does the use of PTNS improve net health outcomes in patients with neurogenic bladder dysfunction?

The following PICOTS were used to select literature to inform this review.

**Patients**

The relevant population of interest is patients with neurogenic bladder dysfunction. Symptoms may include urinating small amounts often, problems starting urination, problems emptying the bladder, inability to detect a full bladder, and losing bladder control.

**Interventions**

The therapy being considered is PTNS. During PTNS, a needle is inserted above the medial malleolus into the posterior tibial nerve followed by the application of low-voltage (10 mA, 1-10 Hz frequency) electrical stimulation. Noninvasive PTNS may be delivered with transcutaneous or surface electrodes. The recommended course of treatment is an initial series of 12 weekly office-based treatments followed by an individualized maintenance treatment schedule.
Comparators
The following therapies are currently being used to make decisions about neurogenic bladder dysfunction: conservative treatments (eg, medication to relax the bladder or to activate pelvic muscles, catheterization to empty the bladder, pelvic floor muscle training), botulinum toxin and SNS.

Botulinum toxin is injected into the detrusor muscle. However, the toxin increases the risk of urinary retention and is not recommended for patients with a history of urinary retention or recurrent urinary tract infections.

SNS may be conducted in an outpatient clinical setting using temporary wire leads. Due to the incidences of lead migration, a 2-step process in a surgical setting is recommended. In the initial test phase, wire leads are inserted under the skin and if 50% improvement is reported, the patient may elect permanent implantation with a pacemaker-like stimulator. If the test phase is unsuccessful, the leads are then removed.

Outcomes
The general outcomes of interest are reduced symptoms and improved quality of life.

Timing
Outcomes are measured following the 12-week treatment regimen.

Setting
PTNS is administered in an outpatient clinical setting.

Systematic Reviews
Schneider et al (2015) published a systematic review on tibial nerve stimulation (transcutaneous and percutaneous) for treating neurogenic lower urinary tract dysfunction. In a literature search through January 2015, 16 studies were identified—4 RCTs, 9 prospective cohort studies, 2 retrospective case series, and 1 case report. Sample sizes of the included studies were small; most included fewer than 50 patients, and none had a sample size larger than 100 patients. Three of the 4 RCTs used transcutaneous tibial nerve stimulation (TTNS), and the fourth study, which was conducted in Iran, stated that PTNS was used but did not specify the device. The 4 RCTs included different study populations: women with neurogenic bladder (n=1), men with neurogenic OAB (n=1), multiple sclerosis patients (n=1), and Parkinson disease patients (n=1). Comparison interventions were tolterodine, pelvic floor muscle training, lower-limb stretching, and sham (1 study each). Pooled analyses were not conducted, and the systematic review mainly discussed intermediate outcomes (eg, maximum cystometric capacity, maximum detrusor pressure). None of the RCTs reported statistically significant between-group differences in clinical outcome variables (eg, number of episodes of urgency, frequency, nocturia).
Section Summary: Neurogenic Bladder Dysfunction
Few RCTs evaluating tibial nerve stimulation for treating neurogenic bladder have been published to date, and all but one performed transcutaneous stimulation rather than PTNS. Studies varied widely in study populations and comparator interventions. Study findings have not suggested that tibial nerve stimulation significantly reduces incontinence symptoms and improves other outcomes.

Fecal Incontinence
The Urgent PC Neuromodulation System is not cleared by the Food and Drug Administration for the treatment of fecal incontinence.

Clinical Context and Therapy Purpose
The purpose of PTNS in patients who have fecal incontinence is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does the use of PTNS improve net health outcomes in patients with fecal incontinence?

The following PICOTS were used to select literature to inform this review.

Patients
The relevant population of interest is patients with fecal incontinence.

Interventions
The therapy being considered is PTNS. During PTNS, a needle is inserted above the medial malleolus into the posterior tibial nerve followed by the application of low-voltage (10 mA, 1-10 Hz frequency) electrical stimulation. Noninvasive PTNS may be delivered with transcutaneous or surface electrodes. The recommended course of treatment is an initial series of 12 weekly office-based treatments followed by an individualized maintenance treatment schedule.

Comparators
The following therapies are currently being used to make decisions about with fecal incontinence: conservative therapies (eg, medical management, retraining of pelvic floor and abdominal wall musculature, dietary changes), medications, and SNS.

SNS may be conducted in an outpatient clinical setting using temporary wire leads. Due to the incidence of lead migration, a 2-step process in a surgical setting is recommended. In the initial test phase, wire leads are inserted under the skin and if improvement is reported after 2 weeks, the patient may elect permanent implantation with a pacemaker-like stimulator. If the test phase is unsuccessful, the leads are then removed.

Outcomes
The general outcomes of interest are reduced symptoms (eg, self-reported assessment of symptoms, a decrease in number of voids per day) and improved quality of life.
**Timing**
Outcomes are measured following the 6- to 12-week treatment regimen.

**Setting**
PTNS is administered in an outpatient clinical setting.

**Systematic Reviews**
Simillis et al (2018) conducted a systematic review and meta-analysis comparing PTNS with SNS for the treatment of fecal incontinence. The literature search identified 4 studies (1 RCT, 3 nonrandomized prospective studies) including 302 patients (109 undergoing SNS, 193 undergoing PTNS). The Cochrane Collaboration’s risk of bias tool was used to assess study quality. Because none of the studies blinded participants and personnel, the risk of performance and detection biases were high. Attrition and publication biases were not detected. Meta-analysis showed that patients undergoing SNS experienced significant improvements compared with patients undergoing PTNS as measured on the Wexner Fecal Incontinence Score (weighted mean difference, 2.3; 95% CI, 1.1 to 3.4) and fecal incontinence episodes per week (weighted mean difference, 8.1; 95% CI, 4.1 to 12.1).

Edenfield et al (2015) conducted a literature search through November 2013 and identified 17 studies (4 RCTs, 13 case series) on the use of tibial nerve stimulation (percutaneous and transcutaneous) for the treatment of fecal incontinence. Three of the RCTs evaluated transcutaneous electrical nerve stimulation and the other PTNS. The 1 RCT and 4 case series using PTNS reported significant decreases in weekly fecal incontinence episodes following 12 weeks of treatment. The quality of life domain scores (eg, depression, embarrassment, coping, lifestyle) showing significant improvements differed across the PTNS studies.

Horrocks et al (2014) conducted a literature search through February 2013 and identified 12 articles, 6 related to PTNS, 5 related to transcutaneous nerve stimulation, and 1 comparing both methods. One RCT, by George et al (2013), discussed below, was included in the Horrocks et al (2014) and the Edenfield et al (2015) reviews. Horrocks et al (2014) identified 5 case series and an RCT that reported the outcome of 50% or greater reduction in the number of fecal incontinence episodes per week immediately after PTNS treatment. In these studies, a median of 71% of patients (range, 63%-82%) reported at least a 50% reduction in episodes. The Horrocks (2014) analysis did not report on control groups.

**Randomized Controlled Trials**
George et al (2013) published the first sham-controlled trial. Thirty patients (28 women) who had failed conservative therapy for fecal incontinence were randomized to PTNS (n=11), TTNS (n=11), or sham transcutaneous stimulation (n=8). Patients in all groups received a total of 12 treatments given twice weekly for 6 weeks. (This differed from the PTNS manufacturer’s recommended course of 12 weekly treatments.) The primary study end point was at least a 50% reduction
in the mean number of incontinence episodes per week at the end of the 6-week treatment period. Only 1 patient failed to complete the trial, and data were analyzed on an intention-to-treat basis. Nine of 11 patients in the PTNS group, 5 of 11 in the TTNS group, and 1 of 8 in the sham group attained the primary endpoint (p=0.035). The mean number of incontinence episodes per week (standard deviation) at the end of the study was 1.8 (0.8), 5.1 (4.2), and 4.7 (3.5) in the PTNS, transcutaneous nerve stimulation, and sham groups, respectively (p=0.04). These findings are limited by the small sample size and short-term follow-up.

A large sham-controlled randomized trial, known as CONFIDeNT, was by Knowles et al (2015).31 The trial was double-blind and multicenter. A total of 227 patients with fecal incontinence sufficiently severe to warrant intervention (according to the principal investigator at each site) were randomized to PTNS (n=115) or sham stimulation (n=112). Both groups received 12 weekly, 30-minute sessions. The primary outcome was at least a 50% reduction in the mean number of episodes of fecal incontinence per week compared with baseline. The mean number of episodes was calculated from 2-week bowel diaries. Twelve patients withdrew from the trial. After treatment, 39 (38%) of 103 in the PTNS group and 32 (31%) of 102 in the sham group had at least a 50% reduction in the number of fecal incontinence episodes per week. The difference between groups was not statistically significant (adjusted odds ratio, 1.28; 95% CI, 0.72 to 2.28; p=0.396). There was also no significant difference between the PTNS and sham groups in the proportion of patients achieving more than 25%, more than 75%, or 100% reduction in mean weekly episodes. There was, however, a significantly greater reduction in the absolute mean number of weekly fecal incontinence episodes in the PTNS group. The mean number of weekly fecal incontinence episodes in the PTNS group was 6.0 at baseline and 3.5 after treatment compared with 6.9 and 4.8, respectively, in the sham group (mean difference, -2.26; 95% CI, -4.18 to -0.35; p=0.021).

Horrocks et al (2017) conducted a post hoc analysis of data from the CONFIDeNT trial, to evaluate factors associated with the efficacy of PTNS for fecal incontinence.32 Results from the multivariable logistic regression on the outcome of 50% improvement in weekly fecal incontinence episodes found that age, fecal urgency, stool consistency, and severity of fecal incontinence did not affect response to PTNS. Presence of obstructive defecation was the only variable that negatively affected response to PTNS (odds ratio, 0.4; 95% CI, 0.2 to 0.9). Excluding patients with obstructive defecation (n=112) resulted in a significant effect of PTNS compared with sham (49% vs 18%, p=0.002).

Thin et al (2015) published data on PTNS vs SNS for fecal incontinence.33 Forty women were randomized, 17 to PTNS and 23 to SNS. Patients in the PTNS group had an initial course of 12 weekly sessions and received 3 maintenance treatments during the following 2 months. SNS was provided using a 2-stage approach: a test stimulation was conducted first, followed by permanent stimulation if they achieved a decrease in fecal incontinence episodes of at least 50% over the 2-week test period. The primary outcome was a reduction of at least 50% in fecal incontinence episodes per week (as determined by 2-week bowel diaries). Fifteen
women passed temporary SNS and underwent permanent implantation. The proportion of patients who achieved the primary outcome at 6 months was 11 (61%) of 18 in the SNS group and 7 (47%) of 15 in the PTNS group. Rates at 3 months were 9 (47%) of 19 in the SNS group and 6 (38%) of 16 in the PTNS group. The authors did not conduct a direct statistical comparison of SNS and PTNS because the study was a pilot.

**Nonrandomized Studies**
Sanagapalli et al (2018) conducted a retrospective chart review of consecutive patients with multiple sclerosis–related fecal incontinence who had failed conservative therapy and who were subsequently treated with PTNS. Patients (N=33) received 8 weekly treatments of PTNS, with responders receiving an additional 4 weeks of treatment. Subjects were classified as responders based on the Wexner Fecal Incontinence Score if scores at the end of treatment were either half of the baseline score or if the score was less than 10. Twenty-six (79%) of the patients were classified as responders. Responders tended to be more symptomatic at baseline and had greater improvements in quality of life scores.

**Section Summary: Treating Fecal Incontinence**
Few RCTs evaluating PTNS for the treatment of fecal incontinence have been published to date. The available RCTs have not found a clear benefit of PTNS. Neither sham-controlled trial found that active stimulation was superior to sham for achieving the primary outcome of at least a 50% reduction in mean incontinence episodes. The larger sham-controlled randomized trial found a significantly greater decrease in absolute number of weekly incontinence episodes in the active treatment group, but the overall trial findings did not suggest the superiority of PTNS over sham treatment. A meta-analysis of 1 RCT and several observational studies reported that patients receiving SNS experienced significant benefits compared with patients receiving PTNS. A post hoc analysis of the larger trial suggested a subset of patients with fecal incontinence, those without concomitant obstructive defecation, might benefit from PTNS.

**Summary of Evidence**
For individuals who have non-neurogenic urinary dysfunction including overactive bladder and have failed behavioral and pharmacologic therapy who receive an initial course of PTNS, the evidence includes randomized sham-controlled trials, RCTs with an active comparator, and systematic reviews. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. The SUmiT and the OrBIT trials are 2 key industry-sponsored RCTs. Systematic reviews that included these and other published trials have found short-term reductions in voiding dysfunction with PTNS. The largest, highest quality study was the double-blinded, sham-controlled SUmiT trial, which reported a statistically significant benefit of PTNS vs sham at 12 weeks. In an additional, small sham-controlled trial, a 50% reduction in urge incontinent episodes was attained in 71% of PTNS group compared with 0% in the sham group. The nonblinded OrBIT trial found that PTNS was noninferior to medication therapy at 12 weeks. Adverse events were limited to local irritation effects. The
evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have overactive bladder syndrome that has failed behavioral and pharmacologic therapy who respond to an initial course of PTNS who receive maintenance PTNS, the evidence includes observational studies and systematic reviews. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. The SUTMiT and the OrBIT trials each included extension studies that followed individuals who responded to the initial course of PTNS and continued to receive periodic maintenance therapy. There is variability in the interval between and frequency of maintenance treatments, and an optimal maintenance regimen remains unclear. There are up to 36 months of observational data available, reporting that there is a durable effect for some of these patients. While comparative data are not available after the initial 12-week treatment period, the observational data support a clinically meaningful benefit for use in individuals who have already failed behavioral and pharmacologic therapy and who respond to the initial course of PTNS. PTNS may allow such individuals to avoid more invasive interventions. Adverse events appear to be limited to local irritation for both short- and long-term PTNS use. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have neurogenic bladder dysfunction who receive PTNS, the evidence includes several RCTs and a systematic review of RCTs and observational data. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Only a few RCTs evaluating tibial nerve stimulation for treating neurogenic bladder have been published to date, and all but one performed transcutaneous stimulation rather than PTNS. Studies varied widely in factors such as study populations and comparator interventions. Study findings have not reported that tibial nerve stimulation significantly reduced incontinence symptoms and improved other outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have fecal incontinence who receive PTNS, the evidence includes several RCTs and systematic reviews. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. The available RCTs have not found a clear benefit of PTNS. Neither of the sham-controlled trials found that active stimulation was superior to sham for achieving the primary outcome, at least a 50% reduction in mean weekly fecal incontinence episodes. The larger sham-controlled randomized trial did find a significantly greater decrease in the absolute number of weekly incontinence episodes in the active treatment group, but the overall trial findings did not suggest the superiority of PTNS over sham treatment. A meta-analysis of a single RCT and several observational studies reported that patients receiving sacral nerve simulation experienced significant benefits compared with patients receiving PTNS. A post hoc analysis of the larger trial suggested a subset of patients with fecal incontinence (those without concomitant obstructive defecation) may benefit from
PTNS. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Clinical Input**

**Objective**
In 2018, clinical input was sought to help determine whether the use of maintenance percutaneous tibial nerve stimulation for individuals with non-neurogenic urinary dysfunction including overactive bladder who have failed behavioral and pharmacologic therapy and respond to an initial course of percutaneous tibial nerve stimulation would provide a clinically meaningful improvement in the net health outcome and whether the use is consistent with generally accepted medical practice.

**Respondents**
Clinical input was provided by the following physician members identified by a specialty society:

- David A. Ginsberg,a MD, Urology, Female pelvic medicine & reconstructive surgery (FPMRS), University of Southern California identified by American Urological Association (AUA)
- Howard B. Goldman,a MD, Urology, Female pelvic medicine & reconstructive surgery (FPMRS) Cleveland Clinic identified by AUA
- Matthew P. Rutman, MD, Association Professor of Urology, Columbia University identified by Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU).

a Indicates that conflicts of interest related to the topic where clinical input is being sought were identified by this respondent (see Appendix).

Clinical input provided by the specialty society at an aggregate level is attributed to the specialty society. Clinical input provided by a physician member designated by the specialty society or health system is attributed to the individual physician and is not a statement from the specialty society or health system. Specialty society and physician respondents participating in the Evidence Street® clinical input process provide a review, input, and feedback on topics being evaluated by Evidence Street. However, participation in the clinical input process by a special society and/or physician member designated by the specialty society or health system does not imply an endorsement or explicit agreement with the Evidence Opinion published by BCBSA or any Blue Plan.
Clinical Input Responses

<table>
<thead>
<tr>
<th>Clinical Indication</th>
<th>Respondent</th>
<th>Identified By</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maintenance PTNS in individuals with non-neurogenic urinary dysfunction including overactive bladder who have failed behavioral and pharmacologic therapy and who respond to an initial course of PTNS</td>
<td>Dr. Ginsberg**</td>
<td>AUA</td>
</tr>
<tr>
<td></td>
<td>Dr. Goldman**</td>
<td>AUA</td>
</tr>
<tr>
<td></td>
<td>Dr. Rutman</td>
<td>SUFU</td>
</tr>
</tbody>
</table>

** Indicates that conflicts of interest related to the topic where clinical input is being sought were identified by this respondent (see Appendix 1).

Additional Comments

- “In regards to duration we maintain patients on a monthly treatment. We do not give them leeway in regards to symptoms such that they might be stimulated more often.” (Dr. Ginsberg identified by AUA)
- “Patients typically have it done once a week for 12 weeks and then, if successful, every 4-6 weeks after that. They are seen in office by MD on a yearly basis to ensure efficacy is continuing.” (Dr. Goldman identified by AUA)
- “Management criteria would be once a week for 12 weeks and monthly afterward for maintenance.” (Dr. Rutman identified by SUFU)

See Appendices 1 and 2.

Supplemental Information

Clinical Input From Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2018 Input

In response to requests, clinical input on use of maintenance percutaneous tibial nerve stimulation (PTNS) for individuals with non-neurogenic urinary dysfunction including overactive bladder who have failed behavioral and pharmacologic therapy and respond to an initial course of PTNS was received from 3 physician respondents identified by specialty societies while this policy was under review in 2018.

Based on the evidence and independent clinical input, the clinical input supports that the following indication provides a clinically meaningful improvement in the net health outcome and is consistent with generally accepted medical practice:
Use of monthly maintenance PTNS for individuals with non-neurogenic urinary dysfunction including overactive bladder who have failed behavioral and pharmacologic therapy and respond to an initial course of PTNS.

### 2012 Input
In response to requests, input was received through 3 physician specialty societies and 1 academic medical center while this policy was under review in 2012. Input was mixed. There was no consensus or near-consensus that the policy should be changed. The range of opinions included that PTNS should be considered investigational, that it should be considered for use in medically refractory patients as second-line treatment, and that the evidence is sufficient to consider this treatment to be medically necessary.

### Practice Guidelines and Position Statements

**American Urological Association et al**
The American Urological Association and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (2015) published guidelines on the diagnosis and treatment of non-neurogenic overactive bladder in adults. The guidelines included a statement that clinicians may offer percutaneous tibial nerve stimulation (PTNS) as a third-line treatment option in carefully selected patients. The statement carried a grade C rating, indicating that the balance of benefits and risks/burdens are uncertain.

**American College of Obstetricians and Gynecologists**
The American College of Obstetricians and Gynecologists (2015) practice bulletin on the treatment of urinary incontinence in women did not address PTNS or other types of nerve stimulation.

**American Gastroenterological Association**
The American Gastroenterological Association (2017) issued an expert review and clinical practice update on surgical interventions and device-aided therapy for the treatment of fecal incontinence. The update stated that “until further evidence is available, percutaneous tibial nerve stimulation should not be used for managing FI [fecal incontinence] in clinical practice.”

**European Association of Urology**
The European Association of Urology (2018) conducted a review of third-line therapies for patients with overactive bladder who do not respond to bladder training or pharmacotherapy. The Association found that botulinum toxin, PTNS, and sacral nerve stimulation may be effective treatments for OAB. There was no high-quality evidence showing the superiority of one therapy over another. Age, comorbidities, patient preference, and surgical expertise were factors to be considered when treatment decisions are made. Table 7 compares the treatment options.
### Table 7. Comparisons of SNM, PTNS, and Botulinum Toxin as Treatments for Overactive Bladder

<table>
<thead>
<tr>
<th></th>
<th>SNM</th>
<th>PTNS</th>
<th>Botulinum Toxin Type A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FDA/EC approval</strong></td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Long-term results</strong></td>
<td>Yes</td>
<td>No</td>
<td>Limited</td>
</tr>
<tr>
<td><strong>Advantages</strong></td>
<td>Minimally invasive</td>
<td>Noninvasive</td>
<td>Minimally invasive</td>
</tr>
<tr>
<td></td>
<td>Effective for urinary and</td>
<td>Uncomplicated procedure</td>
<td>Direct effect</td>
</tr>
<tr>
<td></td>
<td>bowel disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Disadvantages</strong></td>
<td>Permanent implant</td>
<td>May need to repeat procedure every 8-12 wk</td>
<td>Repeat after 6-12 mo</td>
</tr>
<tr>
<td></td>
<td>Battery replacement every</td>
<td>Inferior efficacy</td>
<td>Need for CISC</td>
</tr>
<tr>
<td></td>
<td>5-8 y</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Reversibility</strong></td>
<td>Removal of implant</td>
<td>Instantly reversible</td>
<td>After 6 mo</td>
</tr>
<tr>
<td><strong>Adverse events</strong></td>
<td>Wound infection</td>
<td>None</td>
<td>Urinary retention</td>
</tr>
<tr>
<td></td>
<td>Device-related pain</td>
<td></td>
<td>Urinary tract infection</td>
</tr>
<tr>
<td></td>
<td>Device malfunction</td>
<td></td>
<td>Hematuria</td>
</tr>
</tbody>
</table>

Adapted from Marcelissen et al (2018).

CISC: clean intermittent self-catheterization; EC: European Commission; FDA: Food and Drug Administration; PTNS: percutaneous tibial nerve stimulation; SNM: sacral neuromodulation.

### U.S. Preventive Services Task Force Recommendations
Not applicable.

### Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

### Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 8.

### Table 8. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ongoing</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01162525</td>
<td>Percutaneous Tibial Nerve Stimulation (pTNS) for Patients With Fecal Urge Incontinence</td>
<td>100</td>
<td>Dec 2017 (ongoing)</td>
</tr>
<tr>
<td>NCT02299544</td>
<td>Safety and Performance of the BlueWind System for the Treatment of Patients With Overactive Bladder (OAB)</td>
<td>36</td>
<td>Aug 2018</td>
</tr>
<tr>
<td>NCT02888899</td>
<td>Percutaneous Tibial Nerve Stimulation in Combination With Biofeedback in Patients With Fecal Incontinence - A Randomized Controlled Trial</td>
<td>Unknown</td>
<td>Mar 2019</td>
</tr>
<tr>
<td>NCT03547518</td>
<td>Sham Controlled Trial of Rapid Induction Percutaneous Tibial Nerve Stimulation</td>
<td>64</td>
<td>May 2020</td>
</tr>
<tr>
<td>NCT02190851</td>
<td>Evaluation of Treatment by Transcutaneous Electrical Nerve Stimulation (TENS) of the Posterior Tibial Nerve for Lower Urinary Tract Disorders in</td>
<td>220</td>
<td>Dec 2020</td>
</tr>
</tbody>
</table>
Percutaneous Tibial Nerve Stimulation 7.01.106

Unpublished

| NCT02657057 | Effects of Transcutaneous and Percutaneous PTNS on Idiopathic OAB | 68 | Mar 2017 (completed) |
| NCT01940367 | Percutaneous Tibial Nerve Stimulation vs. Transcutaneous Electrical Nerve Stimulation for Overactive Bladder: A Randomized Trial | 114 | Dec 2017 (unknown) |

NCT: national clinical trial.

References


Billing Coding/Physician Documentation Information

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>64566</td>
<td>Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming</td>
</tr>
<tr>
<td>64999</td>
<td>Unlisted procedure, nervous system</td>
</tr>
<tr>
<td>97014</td>
<td>Application of a modality to 1 or more areas; electrical stimulation (unattended)</td>
</tr>
<tr>
<td>97032</td>
<td>Application of a modality to 1 or more areas; electrical stimulation (manual), each 15 minutes</td>
</tr>
<tr>
<td>L8679</td>
<td>Implantable neurostimulator, pulse generator, any type</td>
</tr>
</tbody>
</table>

ICD10 Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>N32.81</td>
<td>Overactive bladder</td>
</tr>
<tr>
<td>N39.41-</td>
<td>Other specified urinary incontinence code range</td>
</tr>
<tr>
<td>N39.498</td>
<td></td>
</tr>
<tr>
<td>R33.0-</td>
<td>Retention of urine code range</td>
</tr>
<tr>
<td>R33.9</td>
<td></td>
</tr>
<tr>
<td>R35.0</td>
<td>Frequency of micturition</td>
</tr>
<tr>
<td>R39.15</td>
<td>Urgency of urination</td>
</tr>
</tbody>
</table>

Prior to 2011, the correct CPT code to use for PTNS needle insertion is the unlisted CPT code 64999. CPT codes for percutaneous implantation of neurostimulator electrodes (i.e., 64553-64565) are not appropriate since PTNS uses percutaneously inserted needles and wires rather than percutaneously implanted electrodes. The stimulation devices used in PTNS and PNT are not implanted, so CPT code 64590 is also not appropriate.

Additional Policy Key Words

N/A

Policy Implementation/Update Information

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>5/1/08</td>
<td>New policy; considered investigational.</td>
</tr>
<tr>
<td>5/1/09</td>
<td>No policy statement changes.</td>
</tr>
<tr>
<td>5/1/10</td>
<td>No policy statement changes.</td>
</tr>
</tbody>
</table>
9/1/10 Coding updated.
1/1/11 Coding updated.
5/1/11 No policy statement changes.
11/1/11 No policy statement changes.
5/1/12 No policy statement changes.
11/1/12 Policy statement revised to add neurogenic bladder to list of investigational indications.
5/1/13 No policy statement changes.
11/1/13 No policy statement changes.
5/1/14 No policy statement changes.
11/1/14 No policy statement changes.
5/1/15 Title changed to “Percutaneous Tibial Nerve Stimulation.” “Posterior” changed to “percutaneous” in existing policy statement. Policy statement edited to investigational for all indications with bullet points for urinary and fecal incontinence.
11/1/15 No policy statement changes.
5/1/16 No policy statement changes. Added CPT 64999 and 97032
11/1/16 No policy statement changes.
5/1/17 No policy statement changes.
12/1/17 Revised policy statements for use of PTNS in OAB syndrome which has failed behavioral and pharmacologic therapy. In these patients, PTNS is considered medically necessary as initial course of therapy and maintenance therapy for individuals who respond to initial course.
6/1/18 Updated second Medically Necessary statement wording: Maintenance therapy using monthly percutaneous tibial nerve stimulation is considered medically necessary for individuals following a 12-week initial course of percutaneous tibial nerve stimulation that resulted in improved urinary dysfunction meeting treatment goals. Added “dysfunction” to Investigational statement
11/1/18 No policy statement changes.

Appendix

Appendix 1: Clinical Input

Appendix Table 1. Respondent Profile

<table>
<thead>
<tr>
<th>No.</th>
<th>Name</th>
<th>Degree</th>
<th>Institutional Affiliation</th>
<th>Clinical Specialty</th>
<th>Board Certification and Fellowship Training</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>David A. Ginsberg</td>
<td>MD</td>
<td>University of Southern California</td>
<td>Urology, Female pelvic medicine &amp; reconstructive surgery</td>
<td>Urology, Female pelvic medicine &amp; reconstructive surgery</td>
</tr>
<tr>
<td>2</td>
<td>Howard B. Goldman</td>
<td>MD</td>
<td>Cleveland Clinic</td>
<td>Urology</td>
<td>Urology, Female pelvic medicine &amp; reconstructive surgery</td>
</tr>
</tbody>
</table>

Identified by American Urological Association (AUA)

Identified by Society of Urodynamics, Female Pelvic Medicine & Urogenital
Appendix Table 2. Respondent Conflict of Interest Disclosure

<table>
<thead>
<tr>
<th>No.</th>
<th>1. Research support related to the topic where clinical input is being sought</th>
<th>2. Positions, paid or unpaid, related to the topic where clinical input is being sought</th>
<th>3. Reportable, more than $1000, health care–related assets or sources of income for myself, my spouse, or my dependent children related to the topic where clinical input is being sought</th>
<th>4. Reportable, more than $350, gifts or travel reimbursements for myself, my spouse, or my dependent children related to the topic where clinical input is being sought</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes/No Explanation: We are a study site for Bioness – no patients recruited yet</td>
</tr>
<tr>
<td>2</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>3</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

Individual physician respondents answered at individual level. Specialty Society respondents provided aggregate information that may be relevant to the group of clinicians who provided input to the Society-level response.

Appendix 2: Clinical Input Responses

Objective

Percutaneous tibial nerve stimulation (PTNS) (also known as posterior tibial nerve stimulation) is a technique of electrical neuromodulation used primarily for treating voiding dysfunction. The following PICO formulation is of interest for this request.

<table>
<thead>
<tr>
<th>Populations</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individuals: • With non-neurogenic urinary dysfunction including overactive bladder who have failed behavioral and pharmacologic therapy who respond to an initial course of percutaneous tibial nerve stimulation</td>
<td>Interventions of interest are: • Maintenance percutaneous tibial nerve stimulation</td>
<td>Comparators of interest are: • Sacral nerve stimulation • Botulinum toxin</td>
<td>Relevant outcomes include: • Symptoms • Change in disease status • Functional outcomes • Quality of life • Treatment-related morbidity</td>
</tr>
</tbody>
</table>
Clinical input is sought to help determine whether the use of a particular technology for a population would provide a clinically meaningful improvement in net health outcome and whether the use is consistent with generally accepted medical practice.

Responses

1. Based on the evidence and your clinical experience for the use of maintenance PTNS in individuals with non-neurogenic urinary dysfunction including overactive bladder who have failed behavioral and pharmacologic therapy and who respond to an initial course of PTNS, please describe the narrative rationale that includes: (1) relevant authoritative scientific evidence and/or relevant clinical scenarios (e.g., a chain of evidence) supporting that use of the technology provides clinical meaningful improvement in net health outcome; and (2) any relevant patient inclusion/exclusion criteria or clinical context important to achieve a clinically meaningful improvement in net health outcome. Please include the PMID for any relevant references.
   - In particular, please also outline the management criteria, including frequency and duration, for maintenance PTNS treatments to achieve a clinically meaningful improvement in net health outcome.

<table>
<thead>
<tr>
<th>No.</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>I am not sure there is much to add. This review has looked at the relevant studies. I am not aware of medical inclusion/exclusion criteria that help define the optimal patient for this technology. At one point I assumed it would not work on patients with peripheral neuropathy; however, we do have a few patients in our practice that this has helped. The one &quot;exclusion&quot; criteria that we do often see is not medical but geographical - patients that live far away do not want to come to our office weekly for the first 3 months of the treatment. In regards to duration we maintain patients on a monthly treatment. We do not give them leeway in regards to symptoms such that they might be stimulated more often.</td>
</tr>
<tr>
<td>2</td>
<td>At this time there is ample evidence to recommend the use of PTNS in non-neurogenic patients with refractory OAB. It is offered as an alternative to Botox and sacral neuromodulation understanding that while the outcomes of PTNS are not as robust as the others, it is essentially without any significant risk to the patient. Patients typically have it done once a week for 12 weeks and then, if successful, every 4-6 weeks after that. They are seen in office by MD on a yearly basis to ensure efficacy is continuing.</td>
</tr>
<tr>
<td>3</td>
<td>The available literature supports the use of PTNS in patients with non-neurogenic (idiopathic) OAB. There is good data to show it has improvement versus antimuscarinic therapy (Orbit Trial) as well as a sham procedure. There is essentially no risk to the procedure and it is very well tolerated. In my practice, patients respond well and seem to enjoy the ability to be an active participant in treatment for OAB. It is certainly better tolerated and has better compliance than antimuscarinic therapy. Management criteria would be once a week for 12 weeks and monthly afterward for maintenance.</td>
</tr>
</tbody>
</table>

2. Based on the evidence and your clinical experience for each of the clinical indications described in Question 1a and 1b:
a. Respond YES or NO for each clinical indication whether the intervention would be expected to provide a clinically meaningful improvement in net health outcome; AND
b. Rate your level of confidence in your YES or NO response using the 1 to 5 scale outlined below.

<table>
<thead>
<tr>
<th>No.</th>
<th>Indications</th>
<th>Yes/No</th>
<th>Low Confidence</th>
<th>Intermediate Confidence</th>
<th>High Confidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Maintenance PTNS in individuals with non-neurogenic urinary dysfunction including overactive bladder who have failed behavioral and pharmacologic therapy and who respond to an initial course of PTNS</td>
<td>Yes</td>
<td>1</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Maintenance PTNS in individuals with non-neurogenic urinary dysfunction including overactive bladder who have failed behavioral and pharmacologic therapy and who respond to an initial course of PTNS</td>
<td>Yes</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Maintenance PTNS in individuals with non-neurogenic urinary dysfunction including overactive bladder who have failed behavioral and pharmacologic therapy and who respond to an initial course of PTNS</td>
<td>Yes</td>
<td></td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

3. Based on the evidence and your clinical experience for each of the clinical indications described in Question 1a and 1b:
   a. Respond YES or NO for each clinical indication whether this intervention is consistent with generally accepted medical practice; AND
   b. Rate your level of confidence in your YES or NO response using the 1 to 5 scale outlined below.

<table>
<thead>
<tr>
<th>No.</th>
<th>Indications</th>
<th>Yes/No</th>
<th>Low Confidence</th>
<th>Intermediate Confidence</th>
<th>High Confidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Maintenance PTNS in individuals with non-neurogenic urinary dysfunction including overactive bladder who have failed behavioral and pharmacologic therapy and</td>
<td>Yes</td>
<td>1</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>
who respond to an initial course of PTNS

2 Maintenance PTNS in individuals with non-neurogenic urinary dysfunction including overactive bladder who have failed behavioral and pharmacologic therapy and who respond to an initial course of PTNS  Yes X

3 Maintenance PTNS in individuals with non-neurogenic urinary dysfunction including overactive bladder who have failed behavioral and pharmacologic therapy and who respond to an initial course of PTNS  Yes X

4. Additional narrative rationale or comments and/or any relevant scientific citations (including the PMID) supporting your clinical input on this topic.

No. Additional Comments
1 In regards to question #4, there is high confidence that PTNS is part of the generally accepted medical practice. However, please remember that many practitioners do not offer this technique. This is because many urologists and gynecologists do not optimally embrace 3rd tier options for OAB (e.g., SNS, PTNS, onaotA); this is NOT because they do not believe in the technology.
2 None
3 None

5. Is there any evidence missing from the attached draft review of evidence that demonstrates clinically meaningful improvement in net health outcome? If YES, please share any relevant scientific citations of missing evidence (including the PMID).

No. Yes/No Citations of Missing Evidence
1 Yes This is really a maybe more than a yes. There are 2-3 studies evaluating the outcomes of PTNS in MS and Parkinson's pts that suggest nice outcomes. However, none of them are well done RCTs. Most of these studies include the authors Kabay or Zecca.
2 No
3 No

State and Federal mandates and health plan contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The medical policies contained herein are for informational purposes. The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents Blue KC and are solely responsible for diagnosis, treatment and medical advice. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, photocopying, or otherwise, without permission from Blue KC.